Procedure
Endoscopic Intervention
Endoscopic Intervention is a medical procedure with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
PROCEDURE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph not_applicable
2
50%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Recruiting2
Enrolling by invitation1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (33.3%)
N/A2 (66.7%)
Trials by Status
enrolling_by_invitation125%
recruiting250%
completed125%
Recent Activity
2 active trials
Showing 4 of 4
enrolling_by_invitationnot_applicable
Outcome Analysis of POEM and Endoluminal Therapies
NCT03123835
recruitingnot_applicable
Timing of Endoscopic Intervention for Acute Variceal Hemorrhage: an RCT
NCT04786743
recruitingphase_2
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
NCT07233252
completed
Endoscopic Interventions in Patients With COVID-19
NCT04423003
Clinical Trials (4)
Showing 4 of 4 trials
NCT03123835Not Applicable
Outcome Analysis of POEM and Endoluminal Therapies
NCT04786743Not Applicable
Timing of Endoscopic Intervention for Acute Variceal Hemorrhage: an RCT
NCT07233252Phase 2
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
NCT04423003
Endoscopic Interventions in Patients With COVID-19
All 4 trials loaded
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 4